CAR T-cells plus antibody drug for relapsed large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests two immune-based treatments—first a special type of immunotherapy (CAR T-cells, called axi-cel), then a targeted antibody drug (glofitamab)—for people with large B-cell lymphoma that did not fully respond to their first treatment or came back within a year. The goal is to see if this combination can help more people achieve lasting remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your large B-cell lymphoma did not fully respond to your first treatment, or it came back within 12 months.
- Your first treatment must have included a drug like rituximab (Rituxan) and a type of chemotherapy called an anthracycline.
- You have not had CAR T-cell therapy or glofitamab before.
- Your heart, lungs, kidneys, and liver are working well enough, and you are in generally good health.
- You do not have active lymphoma in your brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new combination of two treatments—glofitamab (a targeted antibody) and CAR-T cell therapy—for people with relapsed or refractory large B-cell lymphoma. It is for patients who have not responded to or have relapsed after at least one prior treatment and have certain high-risk features.
This trial tests combining two therapies—a CAR T-cell treatment and an antibody drug called glofitamab—for people with large B-cell lymphoma that has come back or not responded to initial treatment and has certain high-risk features.
This trial tests a new approach to treating aggressive B-cell lymphomas that have returned or didn't respond to initial chemotherapy. It combines a drug called glofitamab with CAR-T cell therapy (immune cells engineered in the lab to fight cancer) to see if it improves outcomes for patients who are candidates for this advanced treatment.
This trial tests a new combination approach for people whose aggressive B-cell lymphoma has come back or not responded to treatment. It uses a bispecific antibody (a type of drug that helps immune cells attack cancer cells) followed by CAR-T cell therapy (reprogramming your own immune cells to find and kill cancer), sometimes with a stem cell transplant.
This study tests a combination of three treatments—rimegepant, glofitamab, and CAR-T cell therapy—for patients with large B-cell lymphoma that has stopped responding to previous treatments. The goal is to see if this combination can help control the cancer and improve survival.
This trial tests a new drug called glofitamab, combined with standard chemotherapy, for people whose large B-cell lymphoma came back or didn't respond to their first treatment. It aims to see if this combination works better than the usual approach.
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.